Table 3.

Differences in incidence of WUPyV and KIPyV-associated lower respiratory tract infections between fully-immunized children who received 9-valent pneumococcal conjugated vaccine and placebo recipients; per-protocol analysis.

	HIV-infected				HIV-uninfected				Overall
	PCV9 (n = 1180)	Placebo (n = 1182)	Vaccine efficacy (95% CI)	p-value	PCV9 (n = 17,065)	Placebo (n = 17,086)	Vaccine efficacy (95% CI)	p-value	PCV9 (n = 18,245)	Placebo (n = 18,268)	Vaccine efficacy (95% CI)	p-value
WUPyV-positive clinical pneumonia	18	15	−20.2	0. 60	18	35	48.5	0.02	36	50	27.9	0.13
			(−101.7, 61.2)				(9.1, 70.8)				(−10.6, 53.0)
WUPyV single-detection clinical pneumoniaa	5	9	44.4	0.42	6	11	45.4	0.23	11	20	44.9	0.11
			(−65.6, 81.3)				(−47.6, 79.8)				(−14.9, 73.6)
WUPyV-positive bronchiolitis	2	1	−100.3	0.63	22	23	4.2	0.89	24	24	−0.13	0.10
			(−2106.4, 81.8)				(−71.8, 46.6)				(−76.2, 43.1)
WUPyV-positive LRTI	20	16	−25.2	0.50	40	56	28.5	0.10	60	72	16.6	0.30
			(−140.4, 34.8)				(−7.3, 52.3)				(−17.5, 40.7)
WUPyV single-detection LRTIa	5	9	44.4	0.42	11	15	26.6	0.43	16	24	33.2	0.21
			(65.6, 81.3)				(−59.8, 66.3)				(−25.6, 64.5)
KIPyV-positive clinical pneumonia	14	17	17.5	0.59	4	20	80.0	0.001	18	37	51.3	0.01
			(−66.7, 59.2)				(41.4, 93.2)				(14.5, 72.3)
KIPyV single-detection clinical pneumoniaa	3	4	24.9	0.50	1	6	83.3	0.13	4	10	59.9	0.18
			(−234.9, 83.1)				(−38.6, 98.0)				(−27.7, 87.4)
KIPyV-positive bronchiolitis	0	2	100	0.50	5	8	37.4	0.58	5	10	49.9	0.30
							(−91.2, 79.5)				(−46.4, 82.9)
KIPyV-positive LRTI	14	17	17.5	0.59	9	27	66.6	0.003	23	44	47.7	0.01
			(−66.6, 59.2)				(29.1, 84.3)				(13.4, 68.4)
KIPyV single-detection LRTIa	3	4	24.9	0.50	1	8	87.5	0.04	4	12	66.6	0.08
			(−234.9, 83.1)				(0.0, 98.4)				(−3.5, 89.2)

LRTI: lower respiratory tract infections; PCV9: 9-valent pneumococcal conjugate vaccine.

^aSingle-detection: if only one single virus was detected in nasopharyngeal aspirates.